FORM 4
[ X ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response...
0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

Care Capital III LLC
2. Issuer Name and Ticker or Trading Symbol

AGILE THERAPEUTICS INC [ AGRX ]
5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director                      __ X __ 10% Owner
_____ Officer (give title below)      _____ Other (specify below)
(Last)          (First)          (Middle)

PO BOX 276
3. Date of Earliest Transaction (MM/DD/YYYY)

4/18/2018
(Street)

AVON BY THE SEA, NJ 07717
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
6. Individual or Joint/Group Filing (Check Applicable Line)

___ Form filed by One Reporting Person
_ X _ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price

Table II - Derivative Securities Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares

Explanation of Responses:

Remarks:
The reporting persons ceased to be holders of 10% or more of the outstanding common stock of Agile Therapeutics, Inc. (the "Company") on or about April 18, 2018, as disclosed in the Company's proxy statement filed on April 25, 2018. As a result, the reporting persons are no longer subject to Section 16 in connection with transactions in the equity securities of the Company and therefore will no longer report any such transactions on Form 4 or Form 5.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
Care Capital III LLC
PO BOX 276
AVON BY THE SEA, NJ 07717

X

Care Capital Investments III L.P.
PO BOX 276
AVON BY THE SEA, NJ 07717

X

Care Capital Offshore Investments III LP
PO BOX 276
AVON BY THE SEA, NJ 07717

X


Signatures
Care Capital III LLC /s/ David R. Ramsay 7/16/2018
** Signature of Reporting Person Date

Care Capital Investments III L.P., By: Care Capital III LLC, Its General Partner /s/ David R. Ramsay 7/16/2018
** Signature of Reporting Person Date

Care Capital Offshore Investments III LP, By: Care Capital III LLC, Its General Partner /s/ David R. Ramsay 7/16/2018
** Signature of Reporting Person Date


Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
Agile Therapeutics (NASDAQ:AGRX)
Historical Stock Chart
From Feb 2024 to Mar 2024 Click Here for more Agile Therapeutics Charts.
Agile Therapeutics (NASDAQ:AGRX)
Historical Stock Chart
From Mar 2023 to Mar 2024 Click Here for more Agile Therapeutics Charts.